Publications in collaboration with researchers from Kobe City Medical Center General Hospital (1)

2023

  1. Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients with Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

    HemaSphere